Feng Chi Biotech Corp. (TPEX:6744)

Market Cap	269.50M -14.6%
Revenue (ttm)	179.94M +3.8%
Net Income	15.64M -18.9%
EPS	1.01 -18.6%
Shares Out	15.40M
PE Ratio	17.33
Forward PE	n/a
Dividend	0.95 (5.43%)
Ex-Dividend Date	Jul 22, 2025

Volume	10
Average Volume	12,256
Open	17.50
Previous Close	17.50
Day's Range	17.50 - 17.50
52-Week Range	14.60 - 22.10
Beta	0.09
RSI	50.59
Earnings Date	Mar 30, 2026

About Feng Chi Biotech

Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company was founded in 1992 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 32
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6744

Financial Performance

In 2024, Feng Chi Biotech's revenue was 171.10 million, a decrease of -5.25% compared to the previous year's 180.58 million. Earnings were 16.59 million, a decrease of -27.19%.